Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Laura Cunningham

Physician Assistant West Des Moines, IA Physician Assistant

NPI 1326424904 CMS profile 10890496

1441 29Th St Ste 211, West Des Moines, IA 50266

Open in the dashboard

General payments

$128,142

642 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Laura Cunningham of West Des Moines, IA is reported in the CMS Open Payments database as having received $128,142 across 642 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $66,941 173
2024 General $26,510 133
2023 General $20,540 150
2022 General $4,588 115
2021 General $9,561 71

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laura Cunningham
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Laura Cunningham were reported at $66,941. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Laura Cunningham Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $9,561 $132 $37–$438 $132
2022 $4,588 $155 $48–$522 $149
2023 $20,540 $167 $52–$557 $160
2024 $26,510 $178 $55–$600 $164
2025 $66,941 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. ITI, Inc. $36,078 106 payments
  2. AbbVie, Inc. $30,091 187 payments
  3. Axsome Therapeutics, Inc. $25,422 71 payments
  4. E.R. Squibb & Sons, L.L.C. $19,717 41 payments
  5. Novo Nordisk Inc $9,729 75 payments
  6. Idorsia Pharmaceuticals US Inc $3,936 18 payments
  7. Vanda Pharmaceuticals Inc. $447 20 payments
  8. Otsuka America Pharmaceutical, Inc. $418 24 payments
  9. Janssen Pharmaceuticals, Inc $291 9 payments
  10. Jazz Pharmaceuticals Inc. $235 2 payments
  11. Other $1,777 89 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $63,210 39 payments
  2. Consulting Fee $27,574 15 payments
  3. Travel and Lodging $13,048 55 payments
  4. Honoraria $12,250 7 payments
  5. Food and Beverage $11,896 523 payments
  6. Education $165 3 payments
Products named General payments · program years 2021–2025
  1. CAPLYTA Psychiatry $35,529 64 payments
  2. Auvelity $25,378 69 payments
  3. VRAYLAR Neuroscience $25,291 135 payments
  4. RYBELSUS $6,867 55 payments
  5. VRAYLAR Neuroscience $4,451 21 payments
  6. QUVIVIQ $3,936 18 payments
  7. Ozempic $3,199 49 payments
  8. COBENFY $1,832 21 payments
  9. CAPLYTA Psychiatry $549 42 payments
  10. FANAPT $435 19 payments
  11. Other $4,258 227 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

350

Median for Physician Assistant: 241

Drug cost

$25,106

Median for Physician Assistant: $4,110

Branded share of claims

33.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 11 $15,943
Vilazodone Hcl Generic 24 $3,919
Bupropion Xl Bupropion Hcl Brand 90 $1,837
Mirtazapine Generic 53 $913
Duloxetine Hcl Generic 14 $615
Clonazepam Generic 17 $396
Escitalopram Oxalate Generic 17 $312
Quetiapine Fumarate Generic 16 $302
Venlafaxine Hcl Er Venlafaxine Hcl Brand 17 $299
Lorazepam Generic 27 $184

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$15,106

Medicare's payments for the services billed

Medicare patients

18

Average age 73

Services billed

246

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Auvelity
  • Axsome Therapeutics, Inc. $9,847
$9,847 — —
VRAYLAR
  • AbbVie, Inc. $6,632
$6,632 11 —
XYWAV
  • JAZZ PHARMACEUTICALS INC. $235
$235 — —
CAPLYTA
  • ITI, Inc. $179
$179 — —
Wegovy
  • Novo Nordisk Inc $115
$115 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

642 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record